Adjuvant transarterial chemoembolization plus lenvatinib for patients with HCC with MVI after resection: a multicenter retrospective study
The Oncologist · 04.06.2025 · 30 (6)
DOI: 10.1093/oncolo/oyaf139 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, online erschienen am 12.06.2025. Verfasst von Yu-Chao Hou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Liver Neoplasms, Phenylurea Compounds. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science foundation of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai Municipal Health Commission Clinical Research Special Fund for the Health Industry, Clinical Research Plan of Shanghai Hospital Development Center.
Abstract (Originalsprache)
Background
Microvascular invasion (MVI) is a critical prognostic factor affecting long-term survival in patients with hepatocellular carcinoma (HCC). Despite its clinical significance, the optimal postoperative adjuvant therapy for HCC patients with MVI remains undefined. This study aimed to evaluate the efficacy and safety of postoperative adjuvant transarterial chemoembolization (PA-TACE) combined with lenvatinib vs PA-TACE alone in HCC patients with MVI.
Methods
We conducted a retrospective analysis of consecutive HCC patients with MVI who underwent curative-intent resection followed by either PA-TACE alone or PA-TACE plus lenvatinib between 2018 and 2022. To ensure comparability, baseline characteristics were balanced using 1:1 propensity-score matching (PSM). The study outcomes, overall survival (OS) and recurrence-free survival (RFS), were compared between the two treatment groups.
Results
The study included 192 patients, with 106 in the PA-TACE alone group and 86 in the PA-TACE plus lenvatinib group. After PSM, 66 matched pairs were analyzed. The median OS and RFS in the PA-TACE plus lenvatinib group were significantly longer than those in the PA-TACE alone group (43.6 months vs 24.0 months, P = 0.015; and 19.6 months vs 10.2 months, P = 0.025, respectively). Multivariable analysis confirmed that PA-TACE plus lenvatinib was an independent protective factor for both OS and RFS.
Conclusions
The combination of PA-TACE and lenvatinib significantly improves survival outcomes in HCC patients with MVI following curative liver resection compared to PA-TACE alone. These findings suggest that this combined approach may be a more effective adjuvant therapy for this high-risk patient population. Further studies are necessary to validate these results and establish clinical guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
- Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China.
- Department of Hepatobiliary Surgery, No. 971 Hospital of Chinese PLA Navy, Qingdao, People's Republic of China.
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, People's Republic of China.
- Department of Thoracic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
ORCID-Profile: Shu-Qun Cheng
Förderung
- Science foundation of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
- Shanghai Municipal Health Commission Clinical Research Special Fund for the Health Industry
- Clinical Research Plan of Shanghai Hospital Development Center
- National Key Research and Development Program of China
- Shanghai Municipal Health Commission
Zitieren
APA
Hou, Y. C., Feng, J. K., Wang, K., Lou, Z. B., Wei, Q., Wang, X., Tang, Y. J., Liu, Z. H., Xiang, Y. J., Mao, F. F., Gong, L., & Cheng, S. Q. (2025). Adjuvant transarterial chemoembolization plus lenvatinib for patients with HCC with MVI after resection: a multicenter retrospective study. The Oncologist, 30(6). https://doi.org/10.1093/oncolo/oyaf139
Vancouver
Hou YC, Feng JK, Wang K, Lou ZB, Wei Q, Wang X, et al. Adjuvant transarterial chemoembolization plus lenvatinib for patients with HCC with MVI after resection: a multicenter retrospective study. The Oncologist. 2025;30(6). doi:10.1093/oncolo/oyaf139
BibTeX
@article{Hou2025,
author = {Hou, Yu-Chao and Feng, Jin-Kai and Wang, Kang and Lou, Zhen-Bang and Wei, Qian and Wang, Xu and Tang, Ying-Jue and Liu, Zong-Han and Xiang, Yan-Jun and Mao, Fei-Fei and Gong, Lin and Cheng, Shu-Qun},
title = {Adjuvant transarterial chemoembolization plus lenvatinib for patients with HCC with MVI after resection: a multicenter retrospective study},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {6},
doi = {10.1093/oncolo/oyaf139}
}
EUVIMED